Joseph C. Papa

Chairman of the Board, Chief Executive Officer

Mr. Papa has been serving on the Board since May 2016 as chairman and chief executive. He has more than 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries, including 20 years of branded prescription drug experience.

He was CEO of Perrigo Company since 2006 and was appointed chairman in 2007. He resigned from all positions at Perrigo in April 2016. Prior to Perrigo, Papa served as chairman and chief executive officer of Cardinal Health’s Pharmaceutical Technologies and Services business unit (2004 – 2006). He was president and chief operating officer for Watson Pharmaceuticals (2001 – 2004), president of Global Country Operations for Pharmacia’s North American business (2000-2001) and president of Searle’s U.S. Operations (1997-2000). Prior to Searle/Pharmacia, Papa served in a variety of general management, sales, marketing and R&D positions during his 15-year career at Novartis Pharmaceuticals (1983-1997).  During his pharmaceutical industry career, he led teams that successfully launched several blockbuster pharmaceutical products including Lotrel, Diovan and Celebrex, and is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril.

In October 2014, Harvard Business Review ranked Papa 47th on its “2014 Best Performing CEOs in the World.” He was also recognized on Israel-based Calcalist Magazine’s “Best Chief Executive Officer for the Year” list for 2013 and 2014. Additionally, Papa was named one of the World’s Best CEOs by Barron’s magazine in 2012, which noted Perrigo “generated one of the best shareholder returns in the S&P 500 in the past five years.”

He is a past member of the UConn Foundation Board of Directors and currently serves on the Smith & Nephew Board of Directors, where he also serves as chairman of the Remuneration Committee.

Papa holds a BS in pharmacy from the University of Connecticut and an MBA from Northwestern University’s Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut School of Pharmacy.

Robert A. Ingram

General Partner, Hatteras Venture Partners

Mr. Ingram has been serving on the Board of the Company since September 2010 in a variety of roles, most recently as interim Chairman of the Board from January to May 2016. Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer of GlaxoSmithKline. He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000. Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. Mr. Ingram is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation.

Mr. Ingram currently serves on the boards of Regeneron Pharmaceuticals, Inc. (member of compensation committee), Edwards Life Sciences Corporation (member of compensation committee) and CREE, Inc. (lead director, member of compensation committee and governance and nominations committee). He is a former chairman of the board of Elan Corporation, plc and a former director of Allergan Inc., Misys plc, Nortel Networks Corporation, Wachovia Corporation, OSI Pharmaceuticals, Inc., Lowe’s Companies, Pharmaceuticals Product Development Inc, and Valeant Pharmaceuticals International, which was merged into the Company, then known as Biovail Corporation, in September 2010 at which time the Company changed its name to Valeant Pharmaceuticals International, Inc.

Dr. Fred Eshelman

Corporate Director

Dr. Eshelman has been serving on the Board since March 2016. He has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. He is the founder and former Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development, Inc. (PPD), a global contract pharmaceutical research organization providing drug discovery, development and lifecycle management services. Dr. Eshelman was also the founding chairman of Furiex Pharmaceuticals, Inc., a drug development company that collaborated with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development.

Thomas W. Ross

Lead Independent Director

Mr. Ross has been serving on the Board since March 2016, and as Lead Independent Director since June 2016. Mr. Ross is the President Emeritus of the 17-campus University of North Carolina, having served as President from 2011-2016. He currently serves as the Sanford Distinguished Fellow in Public Policy at the Duke University Sanford School of Public Policy and as a Professor of Public Law and Government at the UNC Chapel Hill School of Government. Prior to becoming President of the UNC System, Mr. Ross served as President of Davidson College, executive director of the Z. Smith Reynolds Foundation, director of the North Carolina Administrative Office of the Courts, a Superior Court judge, chief of staff to a U. S. Congressman, a member of a Greensboro, NC law firm and as an Assistant Professor of Public Law and Government at UNC-Chapel Hill’s School of Government. Mr. Ross holds a bachelor’s degree in political science from Davidson College (1972) and graduated with honors from the UNC-Chapel Hill School of Law (1975). Mr. Ross currently serves several boards and has received numerous awards and accolades for his public service and professional achievements.

William A. Ackman

CEO, Pershing Square Capital Management, L.P.

Mr. Ackman has been serving on the Board since March 2016. He is the founder and Chief Executive Officer of Pershing Square Capital Management, L.P. Mr. Ackman currently serves as a member of the board of Canadian Pacific Railway Limited, chairman of the board of The Howard Hughes Corporation, a trustee of the Pershing Square Foundation, a member of the Board of Trustees at The Rockefeller University and a member of the Board of Dean’s Advisors of the Harvard Business School. Mr. Ackman holds an M.B.A. from Harvard Business School and a Bachelor of Arts magna cum laude from Harvard College.

Robert N. Power

Corporate Director

Mr. Power has been serving on the Board of the Company since August 2008. Mr. Power was a faculty member at The Wharton School of Business, University of Pennsylvania, where he taught multinational marketing from 2009 to 2011. Mr. Power has over 25 years’ experience working in the pharmaceutical and biotechnology industry through a number of leadership positions with Wyeth beginning in 1985 through 2007, including Director, New Product Development; Managing Director, U.K./Ireland; Vice President, Global Marketing; President, Europe, Middle East, Africa; President, International; and Executive Vice President, Global Business Operations. Mr. Power also has completed the Director Professionalism course offered by the National Association of Corporate Directors.

Stephen Fraidin

Vice Chairman, Pershing Square Capital Management, L.P.

Mr. Fraidin has been serving on the Board since March 2016. He joined Pershing Square Capital Management, L.P. in 2015 as Vice Chairman. Prior to joining Pershing Square, Mr. Fraidin was a Senior Partner at Kirkland & Ellis LLP and advised major companies and investment firms in acquisitions, mergers, proxy contests, corporate governance engagements and other matters. He received his LL.B. from Yale Law School and his A.B. from Tufts University. Mr. Fraidin is widely recognized as one of the country’s leading M&A lawyers. He was named to the Financial Times’ top ten most innovative lawyers in North America; The International Who’s Who of Mergers & Acquisitions Lawyers top ten “Most Highly Regarded Individuals;” Law360 MVP of the Year for M&A in 2013; and twice as The American Lawyer “Dealmaker of the Year.”

D. Robert Hale

Partner, ValueAct Capital

Mr. Hale has been serving on the Board since August 2015. He is a partner of ValueAct Capital, a governance-oriented investment fund that invests in a concentrated portfolio of public companies and works actively with executives and boards of directors on issues of strategy, capital structure, mergers and acquisitions, and talent management. Prior to joining ValueAct Capital in January 2011, Mr. Hale was a Principal with The Parthenon Group, working in both the Boston and Mumbai offices of Parthenon’s strategic consulting practice, as well as in an investment role at Parthenon’s long-short public equity vehicle, Strategic Value Capital. Mr. Hale is also a director of MSCI, Inc. He has an A.B., cum laude, from Dartmouth College.

Dr. Argeris (Jerry) N. Karabelas

Partner, Care Capital, LLC

Dr. Karabelas has been serving on the Board since June 2016. Since December 2001, Dr. Karabelas has been a Partner at Care Capital, LLC, a life sciences venture firm. Prior to Care Capital, he was the founder and Chairman at Novartis BioVenture Fund. He served as Head of Healthcare and CEO of worldwide pharmaceuticals for Novartis Pharma AG from 1998 to 2000, with responsibilities for Novartis Pharma, Ciba Vision, Generics and strategic and operational leadership of R&D. Before joining Novartis, Dr. Karabelas was Executive Vice President of SmithKline Beecham responsible for U.S. and European operations, regulatory and strategic marketing. He has served on several boards of pharmaceutical and therapeutics companies, including Renovo, plc; Vanda Pharmaceuticals, Inc.; NitroMed, Inc.; SkyePharma, plc; Human Genome Sciences; and Inotek Pharmaceuticals.

Russel C. Robertson

Executive Vice President and Head, Anti-Money Laundering, BMO Financial Group

Mr. Robertson has been serving on the Board since June 2016. He has served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group, a diversified financial services organization, since July 2013. Prior to his current role, he served as Executive Vice President, Business Integration and as Vice Chair at BMO Financial Group. He joined the company as Interim Chief Financial Officer in March 2008 and was appointed Chief Financial Officer in August 2009. Before joining BMO, Mr. Robertson held various senior positions with a number of major accounting firms, including Vice Chair, Deloitte & Touche, LLP in Toronto, from 2002 to 2008, and Canadian Managing Partner, Arthur Andersen, LLP, from 1994 to 2002. Mr. Robertson holds a Bachelor of Arts degree (Honours) from the Ivey School of Business at the University of Western Ontario. Since June 2012, Mr. Robertson has served on the boards of Turquoise Hill Resources and Virtus Investment Partners, Inc.

Amy B. Wechsler, M.D.

M.D., Dermatology

Dr. Wechsler has been serving on the Board since June 2016. She has been a practicing dermatologist in New York City since 2005. Dr. Wechsler is the author of The Mind-Beauty Connection, published in 2008. She is board certified in dermatology and psychiatry and is also an Adjunct Clinical Professor in Psychiatry at the Weill Cornell Medical College. As an expert on skin health, Dr. Wechsler is an active member of several medical professional organizations, including the American Academy of Dermatology; the American Psychiatric Association; the American Academy of Child and Adolescent Psychiatry; the Independent Doctors of New York; The Physicians Scientific Society; and The Skin Cancer Foundation. Dr. Wechsler completed her residency in psychiatry and a fellowship in child and adolescent psychiatry at New York Presbyterian Hospital’s Payne Whitney Clinic. She also completed a residency in dermatology at SUNY Downstate Medical Center.

Sarah B. Kavanagh

Corporate Director

Ms. Kavanagh has been serving on the Board since July 2016. From June 2011 through May 2016, she served as a Commissioner, and since 2014 as Chair of the Audit Committee, at the Ontario Securities Commission. She is currently a director and Chair of the Audit Committee of Hudbay Minerals Inc. and a Trustee and Chair of the Compensation and Governance Committee of WPT Industrial REIT. In addition to her public company directorships, she is a director and Chair of the Audit Committee at the American Stock Transfer & Trust Company LLC and the Canadian Stock Transfer Company, a director and Chair of the Audit and Investment Committee of Sustainable Development Technology Canada, and a director of Canadian Tire Bank. Between 1999 and 2010, Ms. Kavanagh served in various senior investment banking roles at Scotia Capital Inc., including Vice-Chair and Co-Head of Diversified Industries Group, Head of Equity Capital Markets, Head of Investment Banking. Prior to Scotia Capital, she held several senior financial positions with operating companies. She started her career as an investment banker with a bulge bracket firm in NY. Ms. Kavanagh graduated from Harvard Business School with a Masters of Business Administration and received a Bachelor of Arts degree in Economics from Williams College. She completed the Directors Education Program at the Institute of Corporate Directors in May 2011.

Richard U. DeSchutter

Corporate Director

Richard (Dick) U. DeSchutter has been serving on the Board since January 2017. Prior to his retirement, Mr. DeSchutter served as the Chairman and Chief Executive Officer of DuPont Pharmaceuticals Company from July 2000 until its acquisition by Bristol-Myers Squibb in October 2001. Mr. DeSchutter was also a Director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in 2000. Prior to the merger, Mr. DeSchutter was a Director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle & Co., Monsanto's wholly owned pharmaceutical subsidiary.

Mr. DeSchutter currently serves as a director of AuVen Therapeutics and Applied Silver, Inc. He was previously Chairman of Incyte Corporation (2003 to 2015); Durata Therapeutics Inc. (2012 to 2014); and Lead Independent Director (2011 to 2014) and Director (2001 to 2014) of Smith & Nephew plc. Mr. DeSchutter earned a Bachelor of Science degree (1963) and a Master of Science Degree (1965) in Chemical Engineering from the University of Arizona.